Chemokine receptors: multifaceted therapeutic targets

By A. Proudfoot. Nature reviews. Immunology, 2002

784 citations recorded by the source corpus.

Chemokines and their receptors are involved in the pathogenesis of diseases ranging from asthma to AIDS. Chemokine receptors are G-protein-coupled serpentine receptors that present attractive tractable targets for the pharmaceutical industry. It is only ten years since the first chemokine receptor was discovered, and the rapidly expanding number of antagonists holds promise for new medicines to combat diseases that are currently incurable. Here, I focus on the rationale for developing antagonists of chemokine receptors for inflammatory disorders and AIDS, and the accumulating evidence that favours this strategy despite the apparent redundancy in the chemokine system.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/3fc8faa3a4318c20e8c49a84aa5cb308f1c9b8cf

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. P. Barnes
2. Christian Weber
3. R. Bucala
4. A. Zernecke
5. F. Balkwill
6. J. Joyce
7. Lisa M. Coussens
8. D. Hanahan

In Oncology

1. P. Barnes
2. F. Balkwill
3. J. Joyce
4. Lisa M. Coussens
5. A. Mantovani
6. M. Karin
7. A. Sica
8. J. Pollard

Citations in the corpus

• MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment (2007, background): “The growing number of chemokine receptor antagonists shown to interfere with mononuclear cell recruitment add to existing evidence in favor of this therapeutic strategy despite the apparent redundancy in the chemokine syste”
• Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 (2020, positive): “The second arm of the antiviral response involves recruitment and coordination of specific subsets of leukocytes, which is orchestrated primarily by chemokine secretion (Proudfoot, 2002; Sokol and Luster, 2015).”
• Mediators of Chronic Obstructive Pulmonary Disease (2004, background): “Chemokine receptors belong to the 7 transmembrane receptor superfamily of G-protein-coupled receptors, and this makes it possible to discover small molecule inhibitors, which has not been possible for classical cytokine receptors (Proudfoot, 2002).”
• Cancer and the chemokine network (2004, background): “With this in mind, it is possible that drugs that are being tested in inflammatory and autoimmune disease that target the chemokine networ”